- Policy
- KRW 2.85 tln for KDCA COVID-19 vaccine supplementary budget
- by Kim, Jung-Ju Mar 29, 2021 05:58am
- The Korea Disease Control and Prevention Agency (KDCA) has secured an additional budget of 2.35 trillion won for procuring COVID-19 vaccines from overseas. This reflects additional 2.30 trillion won from this year. On Mar. 25, KDCA announced that this increase was reflected as the first supplementary budget in the year 2021. The total cost of
- Policy
- Drug price management office takes care of all drug prices
- by Lee, Hye-Kyung Mar 26, 2021 05:37am
- “Drug Price Management Office of the NHIS is in charge of practical work to apply the results of research services for full-cycle management of pharmaceuticals to the field. It reviews and tries to realize the improvement or reform of the system related to pharmaceuticals. " Kang Cheong-hee, the executive director of the NHIS’ benefit re
- Policy
- Lipilouzet, listed as the highest price for the same formula
- by Kim, Jung-Ju Mar 26, 2021 05:37am
- Lipilouzet, a combination drug of Chong Kun Dang's Atorvastatin Calcium + Ezetimibe, will be listed as the highest price for the same formulation of all combinations. Pfizer Korea's Xeljanz XR Tab 11mg (Tofacitinib Citrate) does not have the same formulation, so it is listed at the same price as the target product. The MOHW is promoting the revi
- Policy
- Reduced drug price by expanding the scope of Abraxane
- by Kim, Jung-Ju Mar 25, 2021 05:58am
- Celgene's anticancer drug Abraxane (Paclitaxel) is expected to cut the drug price by 3.6% next month as the scope of use is expanded. Janssen Korea's prostate cancer treatment Zytiga 500mg (Abiraterone Acetate) is subject to a 5% cut rate due to an additional indication, and advance drug price cuts are being promoted. Takeda Pharmaceutical Ko
- Policy
- MOHW announces list of premium pricing benefit decision
- by Kim, Jung-Ju Mar 25, 2021 05:58am
- The South Korean health authority is to authorize 30-percent reimbursed pricing reduction in every dose of Eisai Korea’s Symbenda injection (bendamustine hydrochloride). After a year, the injection’s pricing would be brought down again by 23.5 percent due to the expired weighted pricing benefit. Novartis Korea’s Afinitor (everolimus) is to ma
- Policy
- CMOs tense up for a full day MFDS investigation
- by Lee, Tak-Sun Mar 23, 2021 06:24am
- Set off by the Binex incident, South Korea’s Ministry of Food and Drug Safety (MFDS) has started a full investigation on pharmaceutical contract manufacturing organizations (CMOs). Although it was a day-long investigation, the companies noted it was pressuring. According to the relevant industry sources on Mar. 22, two to three regional
- Policy
- New benefits for Epidiolex will be established from April
- by Lee, Jeong-Hwan Mar 23, 2021 06:23am
- New standard for Epidiolex (a drug for refractory childhood epilepsy) will be established. Democratic Party of Korea Rep. Nam In-soon and others strongly pointed out the validity of health insurance benefits at last year's national audit. Epidiolex costs about &8361;1.64 million per bottle, and up to &8361;40 million per year. On the 17
- Policy
- “Regular COVID-19 vaccination like flu vaccination"
- by Kim, Jung-Ju Mar 23, 2021 06:23am
- The South Korean health authority says the COVID-19 vaccination could be periodically provided in the future, similar to an influenza vaccination, due to the pandemic still spreading strong around the world. It also means the health authority would have to successfully develop an mRNA vaccine platform, in which the government plans to soo
- Policy
- The HIRA's reimbursed standards for chemotherapy are changed
- by Lee, Hye-Kyung Mar 23, 2021 06:23am
- The HIRA has changed the chemotherapy benefit standard, four criteria are changed and three criteria are deleted in relation to pancreatic cancer chemotherapy. Changes are made in a total of 25 criteria. The HIRA recently prepared an amendment to 'Details on the Standards and Methods of Applying Medical Care Benefits to Drugs Prescribed and A
- Policy
- Pitavastatin-Ezetimibe by JW Pharmaceutical was applied
- by Lee, Tak-Sun Mar 22, 2021 06:18am
- JW Pharmaceutical is participating in the Statin-Ezetimibe hyperlipidemia complex market, which has more than 600 products in Korea. It is a combination of Livalo (Pitavastatin) and Ezetimibe. According to industry sources on the 21st, JW Pharmaceutical recently applied for permission for Pitavastatin-Ezetimibe to the MFDS. It was known as
